Beken Bio, Inc.

Beken Bio, Inc. is a US-based biotechnology firm focused on advancing liquid biopsy technology for early cancer detection, utilizing proprietary innovations to improve diagnostic accuracy and patient outcomes. Beken Bio develops minimally invasive liquid biopsies that leverage its 3D REVEAL™ engine to identify novel cancer biomarkers in blood samples. Headquartered in San Diego, US, the company has undertaken strategic advancements in its technology.

The firm has closed one funding deal, raising an undisclosed amount of pre-seed funding co-led by Community Development Venture Capital Alliance and New Orleans BioFund. Beken Bio specializes in the development of minimally invasive liquid biopsies, utilizing its proprietary 3D REVEAL™ engine to diagnose cancer at its earliest stages. This innovative technology identifies novel cancer biomarkers present in the blood before symptoms manifest, enhancing early detection capabilities. The primary objective of Beken Bio’s offerings is to empower healthcare providers with accurate diagnostic tools, facilitating timely and effective treatment interventions for patients.

The company targets a broad array of clients, including hospitals, diagnostic laboratories, and oncologists, focusing on markets in North America, Europe, and select regions in Asia. By delivering reliable diagnostic tests, Beken Bio aims to reduce cancer-related mortality rates and shift the paradigm towards proactive cancer management. The revenue model of Beken Bio is structured around partnerships with healthcare providers and institutions that integrate its diagnostic solutions into their patient care workflows. The company engages in B2B transactions, supplying its liquid biopsy tests to hospitals and laboratories that then offer these services to their patients.

Revenue is generated through the sale of its flagship product, the 3D REVEAL™ liquid biopsy, which is expected to be billed per diagnostic test performed. Pricing structures may be defined through subscription agreements or direct sales contracts, ensuring healthcare partners have access to the latest advancements in cancer detection technology. These transactional frameworks are designed to foster long-term relationships with clients, supporting a continuous revenue stream as the demand for early cancer detection solutions grows. Beken Bio plans to leverage its recent funding to further develop its 3D REVEAL™ liquid biopsy technology and pursue new product launches aimed at enhancing diagnostic precision.

The company is focusing on expanding its market presence, particularly in Europe and select regions in Asia, with initiatives slated to commence by the end of 2024. The recently acquired pre-seed funding will be utilized to support these developments and market expansion efforts.